Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Roche today announced the submission of a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Venclexta ® (venetoclax) in combination with Gazyva® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - March 7, 2019 Category: Pharmaceuticals Source Type: news

Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Roche today announced the submission of a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Venclexta ® (venetoclax) in combination with Gazyva® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions. (Source: Roche Media News)
Source: Roche Media News - March 7, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Imbruvica (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Na ïve Patients with Chronic Lymphocytic Leukemia
HORSHAM, Pa., Jan. 28, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in combination with obinutuzumab in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 28, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approves First Nonchemo Regimen for CLL/SLL FDA Approves First Nonchemo Regimen for CLL/SLL
This is the first approval of a nonchemotherapy combination for untreated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 28, 2019 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves IMBRUVICA(R) (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Patients treated with IMBRUVICA plus obinutuzumab experienced a 77 percent reduction in risk of progression or death compared to chlorambucil plus obinutuzumab Approval broadens the label in frontline CLL and represents the tenth FDA approval for IMBRUV... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, IMBRUVICA, ibrutinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 28, 2019 Category: Pharmaceuticals Source Type: news

New treatment for adults with chronic lymphocytic leukaemia
NICE is recommending venetoclax with rituximab for adults with relapsed or refractory chronic lymphocytic leukaemia. Thousands of patients should benefit, NICE says. (Source: NHS Networks)
Source: NHS Networks - January 23, 2019 Category: UK Health Source Type: news

New leukemia drug is more effective and easier to use
(Loyola University Health System) A landmark study co-authored by a Loyola Medicine oncologist has found that a newer targeted drug is significantly more effective than standard therapy for treating elderly patients with chronic lymphocytic leukemia (CLL). The drug is taken as a pill once a day -- much more convenient than the standard treatment requiring the patient to come in three times a month for infusions and an injection. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2019 Category: International Medicine & Public Health Source Type: news

Top Discoveries in Chronic Lymphocytic Leukemia at ASH 2018
In an interview withCancer Network, Brad S. Kahl, MD, weighs in on the top CLL research presented at ASH 2018 in San Diego. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

MRD Effective as Surrogate Endpoint in CLL?
A patient ’s minimal residual disease status may serve as a surrogate marker for outcome in clinical trials of chronic lymphocytic leukemia in patients with comorbidities. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Testing and Treatment Patterns Rapidly Changing in CLL
Testing patterns associated with the diagnosis and treatment of chronic lymphocytic leukemia have changed rapidly during the last decade. (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

New Phase 3 Study Findings Show IMBRUVICA ® (ibrutinib) Plus Rituximab Significantly Improved Survival Compared to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Previously Untreated Patients Aged 70 or Younger with Chronic Lymphocytic Leukemia
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 4, 2018 Category: Pharmaceuticals Source Type: news

Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia
Chronic lymphocytic leukemia is one of the most common types of leukemia in adults typically occurring during or after middle age and rarely occurring in individuals under the age of 40. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - December 4, 2018 Category: American Health Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Media News)
Source: Roche Media News - December 4, 2018 Category: Pharmaceuticals Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - December 4, 2018 Category: Pharmaceuticals Source Type: news

Ibrutinib Alone for Older Patients With Untreated CLL Ibrutinib Alone for Older Patients With Untreated CLL
Ibrutinib alone and ibrutinib with rituximab were both superior to the bendamustine – rituximab combination for older patients with chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

IMBRUVICA ® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 3, 2018 Category: Pharmaceuticals Source Type: news

ASH: Ibrutinib Tops Bendamustine & #43; Rituximab for CLL
MONDAY, Dec. 3, 2018 -- For older patients with untreated chronic lymphocytic leukemia (CLL), treatment with ibrutinib alone or in combination with rituximab is associated with improved progression-free survival versus bendamustine plus rituximab,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2018 Category: Pharmaceuticals Source Type: news

For Chronic Leukemia Patients, the News Just Got Even Better
Several chronic lymphocytic leukemia (CLL) patients at the Wilmot Cancer Institute took part in two groundbreaking, nationwide phase 3 studies that are changing the way doctors treat the disease. The positive results are being reported this weekend at the 2018 American Society of Hematology (ASH) annual meeting — and will immediately impact CLL patients in the Rochester region and across the U.S., said Paul Barr, M.D., director of Wilmot’s Clinical Trials Office. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - November 29, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

AbbVie Receives European Commission Approval of VENCLYXTO(R) (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
The approval is based on the MURANO Phase 3 clinical trial, in which VENCLYXTO® plus rituximab reduced the risk of disease progression or death by 83 percent and overall survival was prolonged compared to bendamustine in combination with rituximab, a s... Biopharmaceuticals, Oncology, Regulatory AbbVie, VENCLYXTO, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2018 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
Roche announced today that the randomised phase III CLL14 study, which evaluated fixed-duration Venclexta ®/Venclyxto® (venetoclax) in combination with Gazyva®/Gazyvaro® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death (PFS; as assessed by investigator) compared to standard-of-care Gazyva/Gazyvaro plus chlorambucil. The results showed that no new safety signals or increase in known toxicities of Venclexta/Venclyxto or Ga...
Source: Roche Media News - November 1, 2018 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
Roche announced today that the randomised phase III CLL14 study, which evaluated fixed-duration Venclexta ®/Venclyxto® (venetoclax) in combination with Gazyva®/Gazyvaro® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death (PFS; as assessed by investigator) compared to standard-of-care Gazyva/Gazyvaro plus chlorambucil. The results showed that no new safety signals or increase in known toxicities of Venclexta/Venclyxto or Ga...
Source: Roche Investor Update - November 1, 2018 Category: Pharmaceuticals Source Type: news

Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Media News)
Source: Roche Media News - November 1, 2018 Category: Pharmaceuticals Source Type: news

Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - November 1, 2018 Category: Pharmaceuticals Source Type: news

NICE rejects AbbVie leukemia drug over price
NICE gave a negative opinion on AbbVie ’s Venclyxta in combination with Roche’s Rituxan, for treating relapsed or refractory chronic lymphocytic leukaemia in adults. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 26, 2018 Category: Pharmaceuticals Source Type: news

Researchers in Barcelona awarded with one of the most prestigious EU grants to unravel CLL
(Center for Genomic Regulation) The European Research Council today announced the results of the 2018 ERC Synergy Grants Call. A project, the BCLL@las, of four research groups from the Centro Nacional de An á lisis Gen ó mico of the Centre for Genomic Regulation, and the Institut d'Investigacions Biom è diques August Pi i Sunyer have received this prestigious grant to unravel the genomics and epigenomics of chronic lymphocytic leukemia at unprecedented resolution using single-cell analysis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 26, 2018 Category: Cancer & Oncology Source Type: news

AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatment The submission is based on positive results from the Phase 3 iLLUMINATE (PCYC-1130) trial, which sho... Biopharmaceuticals, Oncology, FDA AbbVie, IMBRUVICA, ibrutinib, obinutuzumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 17, 2018 Category: Pharmaceuticals Source Type: news

Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL
Duvelisib extended progression - free survival to 13.3 months versus 9.9 months for ofatumumab (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 10, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL
WEDNESDAY, Oct. 10, 2018 -- For patients with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), the oral, dual inhibitor of phosphoinositide 3-kinase- δ and -γ, duvelisib, seems effective, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 10, 2018 Category: Pharmaceuticals Source Type: news

MD Anderson and Cyclacel Pharmaceuticals announce strategic alliance to study novel Cyclacel medicin
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 4, 2018 Category: Cancer & Oncology Source Type: news

Duvelisib has marked response, survival benefit in difficult-to-treat leukemia and lymphoma
(American Society of Hematology) For some patients with difficult-to-treat leukemia and lymphoma, the investigational oral medicine duvelisib may significantly improve disease outcomes, according to phase III trial data published today in the journal Blood. The DUO trial studied duvelisib versus ofatumumab, an approved standard-of-care chemotherapy for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). According to the study, duvelisib extended PFS from a median of 9.9 months on ofatumumab to 13.3 months. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 4, 2018 Category: Cancer & Oncology Source Type: news

Duvelisib Approved for Certain Lymphomas Duvelisib Approved for Certain Lymphomas
The FDA approved the new drug for use in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma.FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Copiktra (duvelisib) Capsules for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
BOSTON--(BUSINESS WIRE)--Sep. 24, 2018-- Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 24, 2018 Category: Drugs & Pharmacology Source Type: news

Roche announces CHMP recommendation for EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - September 21, 2018 Category: Pharmaceuticals Source Type: news

Critically Elevated Potassium in Chronic Lymphocytic Leukemia Critically Elevated Potassium in Chronic Lymphocytic Leukemia
A misdiagnosis as to the cause of hyperkalemia in this patient led to unnecessary dialysis, demonstrating the need to be alert to potentially false potassium results in patients with elevated WBC counts.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2018 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Stress linked to more advanced disease in some leukemia patients
(Ohio State University) Patients with chronic lymphocytic leukemia (CLL) who feel more stress also have more cancer cells in their blood and elevated levels of three other markers of more advanced disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2018 Category: Cancer & Oncology Source Type: news

Melanoma Linked with CLL, Wilmot Recommends Close Monitoring
While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery — these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of skin cancer. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - August 14, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Medical News Today: What is the outlook for chronic lymphocytic leukemia?
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. Although doctors can very rarely cure CLL, survival rates for this cancer are typically good. A person ’s life expectancy for CLL depends on how far the cancer has progressed and when they receive treatment. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 13, 2018 Category: Consumer Health News Tags: Leukemia Source Type: news

Melanoma linked with CLL, close monitoring recommended
(University of Rochester Medical Center) While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery -- these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of skin cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 9, 2018 Category: International Medicine & Public Health Source Type: news

Mutations in Half of Patients With CLL Who Relapse on Ibrutinib Mutations in Half of Patients With CLL Who Relapse on Ibrutinib
Acquired mutations were present in 50% of patients with chronic lymphocytic leukemia (CLL) who relapsed after treatment with ibrutinib (Imbruvica).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Survival Longer With Obinutuzumab Compared to Rituximab in CLL Survival Longer With Obinutuzumab Compared to Rituximab in CLL
New longer-term results with overall survival data confirm the superiority of the newer agent over the earlier-generation anti-CD20 drug rituximab for previously untreated chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 20, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
83 percent (n=100) of 121 patients who achieved undetectable minimal residual disease (uMRD) at the end of combination therapy with VenR (n=194), maintained uMRD and were progression-free at 13.8 months of follow-up[1] uMRD response rates were consisten... Biopharmaceuticals, Oncology AbbVie, MURANO trial, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 15, 2018 Category: Pharmaceuticals Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the final analysis of the CLL11 study evaluating Gazyva®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: World Pharma News)
Source: World Pharma News - June 15, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Media News)
Source: Roche Media News - June 15, 2018 Category: Pharmaceuticals Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Investor Update)
Source: Roche Investor Update - June 15, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Roche, announced today that the United States Food and Drug Administration (FDA) has approved Venclexta ® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. (Source: Roche Media News)
Source: Roche Media News - June 11, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Roche, announced today that the United States Food and Drug Administration (FDA) has approved Venclexta ® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - June 11, 2018 Category: Pharmaceuticals Source Type: news

The cancer revolution: How you can benefit from a new test which could mean no more chemo
Mike Brandon, 34, from Bristol was diagnosed with chronic lymphocytic leukaemia which is deemed untreatable in the UK but he was able to undergo specialised life-saving therapy in the US. (Source: the Mail online | Health)
Source: the Mail online | Health - June 10, 2018 Category: Consumer Health News Source Type: news

Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia
South San Francisco, CA -- June 8, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with Rituxan ... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 8, 2018 Category: Drugs & Pharmacology Source Type: news

Ibrutinib Plus Venetoclax Shows Promising Activity Against CLL
Bryant FurlowJun 4, 2018In CAPTIVATE, first-line ibrutinib plus venetoclax yielded a high rate of undetectable residual disease, without new safety signals, in chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news